Business Wire

PUUSTELLI-GROUP

19.3.2020 09:28:05 CET | Business Wire | Press release

Share
Puustelli Group: Water-resistant Biocomposite for Puustelli Bathroom Fittings

Puustelli has innovated a unique furniture system to eliminate moisture problems in bathroom fittings. The furniture frames feature a structure made of biocomposite by injection moulding. The biocomposite is a mixture of polypropylene and chemical pulp fibre, and is a water-resistant, non-toxic, ecological, modifiable and lasting material. This Finnish product innovation has been developed and is made 100% in Finland. The furniture system, which is suitable for kitchen furniture, has been in production in Puustelli Miinus kitchens since back in 2013. Puustelli was granted a European patent for its invention in 2018.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200319005234/en/

Water-resistant material
Most bathroom fittings typically have a frame of MDF or particleboard, both of which have poor moisture resistance. The biocomposite frame in Puustelli bathroom fittings can fully withstand water and comes with a 30-year guarantee.

Low-emission concept
Formaldehyde is also present in the panel materials typically used in bathroom fittings. When emitted into the indoor air, formaldehyde is harmful to the health. Even when the panel structure is only slightly damaged, the impact of moisture multiplies the harmful effects. The Puustelli biocomposite frame has a formaldehyde content of exactly 0%. Not only that, the biocomposite is antistatic and does not attract dust.

Ecological solution
Once a frame made from conventional furniture board has absorbed moisture, it can no longer be repaired and must be disposed of and replaced. The Puustelli biocomposite frame on the other hand is a fully reusable and recyclable material. Since it is recyclable, any waste raw material originating in the manufacturing process of the Puustelli biocomposite frame can be efficiently reused.

Puustelli bioframe can be modified
Unlike traditional frame materials, the Puustelli bioframe doesn’t tire of modification or being moved. The frame has precise dimensional accuracy and fittings and materials that affect its appearance can be switched around numerous times if required without the screw fastenings becoming fatigued. The furniture is available for large and small spaces alike. The frames can be finished in various ways depending on the range. Puustelli has also developed from the composite for the frame, a design end panel with a restrained pattern suitable for different styles. Small locators have also been made in the panel in conjunction with injection moulding to make it easy to screw the end panel accurately into the ready-made holes in the frame. The bioframes of the washbasin cupboards have been designed for careful use of space. Plumbing has also been taken into account and if necessary can easily be accessed later. Base cabinets come at a height of 613 mm and widths vary between 200 mm and 1200 mm depending on the model. Since the depth is just 370 mm, they can fit into small spaces.

“The bathroom product development process has been long and at times challenging, but the outcome was well worth all the work. Following our kitchen furniture, a similar bathroom fitting innovation was already anticipated and is now in production,” says Jussi Aine, CEO, Puustelli Group Oy. 

Puustelli Group Oy is a Finnish family enterprise and part of the century-old Harjavalta Group, which also includes Kastelli Group Oy and Lapti Group Oy. The Group had a turnover of €491 million in 2019.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye